https://kuraoncology.com/wp-content/uploads/Screenshot-2023-08-23-at-6.38.57-PM.png
1172
2338
Emily Hennes
/wp-content/uploads/kura-logo.svg
Emily Hennes2023-08-23 17:17:322023-08-24 08:43:04Evaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML
https://kuraoncology.com/wp-content/uploads/Video-1-thumbnail.png
235
422
eallison
/wp-content/uploads/kura-logo.svg
eallison2023-06-16 13:46:022023-08-23 17:46:15Emerging advancements in acute myeloid leukemia
https://kuraoncology.com/wp-content/uploads/Video-2-thumbnail.png
235
422
eallison
/wp-content/uploads/kura-logo.svg
eallison2023-06-16 13:47:032023-08-23 17:06:30Can you give a brief overview of unmet medical needs within NPM1-mutated acute myeloid leukemia?
https://kuraoncology.com/wp-content/uploads/Fathi_testing_thumbnail.jpg
235
422
eallison
/wp-content/uploads/kura-logo.svg
eallison2023-08-08 16:40:522023-08-23 17:06:48NPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials
https://kuraoncology.com/wp-content/uploads/Mechanism-of-action-for-investigational-menin-inhibitors-including-ziftomenib.jpg
235
422
eallison
/wp-content/uploads/kura-logo.svg
eallison2023-08-08 16:12:302023-08-23 17:07:13Mechanism of action for investigational menin inhibitors, including ziftomenib
https://kuraoncology.com/wp-content/uploads/Fathi_r2_long_thumbnail.png
640
1137
eallison
/wp-content/uploads/kura-logo.svg
eallison2023-09-19 10:54:002023-09-19 10:57:37Dr. Fathi presents the latest KOMET-001 data
Scroll to top